Sanofi: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...
Sanofi stock price target raised to €120 by Leerink Partners
Sanofi (SAN:FP) (NASDAQ: NASDAQ:SNY) saw its price target increased by Leerink Partners from €113.00 to €120.00, while the firm maintained an Outperform rating on the company's shares. Currently ...
PharmiWeb12m
Global Yeast Infection Treatment Market Set to Surge to USD 10031.3 Million by 2034, Driven by Strong CAGR of 5.0%, According to FMI Report
Yeast Infection Treatment MarketFuture Market Insights (FMI), a leading market research firm, has released a new industry analysis revealing an impressive upsurge in the global yeast infection ...